FCPR03|cas:1917347-65-9|西域试剂

FCPR03,99.82%

产品编号：Bellancom-117977| CAS NO：1917347-65-9| 分子式：C₁₅H₁₉F₂NO₃| 分子量：299.31

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-117977	￥3000.00	杭州北京（现货）
Bellancom-117977	￥4800.00	杭州北京（现货）
Bellancom-117977	￥9500.00	杭州北京（现货）
Bellancom-117977	￥14500.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

FCPR03

产品介绍

FCPR03 是一种有效的选择性的磷酸二酯酶 4 (PDE4) 抑制剂，对于 PDE4 催化域，PDE4B1 和 PDE4D7，IC₅₀ 值分别为 60 nM，31 nM 和 47 nM。FCPR03 对 PDE4 的选择性比其他 PDE (PDE1-3 和 PDE5-11) 至少高 2100 倍。FCPR03 具有抗炎，神经保护和抗抑郁样作用。

生物活性

FCPR03 is a potent and selective phosphodiesterase 4 (PDE4) inhibitor with IC₅₀ values of 60 nM, 31 nM and 47 nM for PDE4 catalytic domain, PDE4B1 and PDE4D7, respectively. FCPR03 displays at least 2100-fold selectivity over other PDEs (PDE1-3 and PDE5-11). FCPR03 has anti-inflammatory, neuroprotective and antidepressant-like effects.

体外研究

FCPR03 (5-20 μM; 30 hours; HT-22 cells) treatment increases cell viability (oxygen-glucose deprivation (OGD)-induced) in a dose-dependent manner, and 10 μM FCPR03 shows significant protective effects.
FCPR03 (20 μM; 30 hours; HT-22 cells) treatment protects against OGD-induced cellular apoptosis in both HT-22 cells and cortical neurons. The levels of mitochondrial membrane potential (MMP) and ROS are also restored by FCPR03.
FCPR03 (20 μM; 30 hours; HT-22 cells) treatment increases the levels of phosphorylated AKT, glycogen synthase kinase-3β (GSK3β), and β-catenin.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay

Cell Line:	HT-22 cells
Concentration:	5 μM, 10 μM, 20 μM
Incubation Time:	30 hours
Result:	Increased cell viability in a dose-dependent manner.

Apoptosis Analysis

Cell Line:	HT-22 cells
Concentration:	20 μM
Incubation Time:	30 hours
Result:	Reversed the effects of OGD and decreased the ratio of apoptotic cells.

Western Blot Analysis

Cell Line:	HT-22 cells
Concentration:	20 μM
Incubation Time:	30 hours
Result:	Increased the levels of phosphorylated AKT, glycogen synthase kinase-3β (GSK3β), and β-catenin.

体内研究
(In Vivo)

FCPR03 (1.25-5 mg/kg; intraperitoneal injection; once; adult male Sprague-Dawley rats) treatment reduces the infarct volume and improves neurobehavioral outcomes in rats following MCAO. FCPR03 increases the levels of phosphorylated AKT, GSK3β and β-catenin within the ischemic penumbra of rats following cerebral ischemia-reperfusion.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Adult male Sprague-Dawley rats (250-280 g) induced middle cerebral artery occlusion (MCAO)
Dosage:	1.25 mg/kg, 2.5 mg/kg, 5 mg/kg
Administration:	Intraperitoneal injection; once
Result:	Reduced the infarct volume and improved neurobehavioral outcomes in rats following MCAO.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Adult male Sprague-Dawley rats (250-280 g) induced middle cerebral artery occlusion (MCAO)
Dosage:	1.25 mg/kg, 2.5 mg/kg, 5 mg/kg
Administration:	Intraperitoneal injection; once
Result:	Reduced the infarct volume and improved neurobehavioral outcomes in rats following MCAO.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Adult male Sprague-Dawley rats (250-280 g) induced middle cerebral artery occlusion (MCAO)
Dosage:	1.25 mg/kg, 2.5 mg/kg, 5 mg/kg
Administration:	Intraperitoneal injection; once
Result:	Reduced the infarct volume and improved neurobehavioral outcomes in rats following MCAO.

性状

Solid

溶解性数据

In Vitro:

DMSO : 100 mg/mL (334.10 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	3.3410 mL	16.7051 mL	33.4102 mL
5 mM	0.6682 mL	3.3410 mL	6.6820 mL
10 mM	0.3341 mL	1.6705 mL	3.3410 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式